Abiopharma

🔍 Doberstein Stephen K (Executive)

Company: Forte Biosciences, Inc. (FBRX)

Report Date: 2026-08-27

Detailed Transactions and Holdings:

• Sold 2,000 shares of Stock Option (right to buy) at $29.5 per share (Derivative)
  Date: 2026-08-27 | Code: D | Expires: 2032-05-12 | Exercise: 2025-05-12 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,000 shares of Stock Option (right to buy) at $31.75 per share (Derivative)
  Date: 2026-08-27 | Code: D | Expires: 2032-06-01 | Exercise: 2023-06-01 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 1,000 shares of Stock Option (right to buy) at $20.0 per share (Derivative)
  Date: 2026-08-27 | Code: D | Expires: 2033-09-19 | Exercise: 2024-08-20 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 2,000 shares of Stock Option (right to buy) at $8.6 per share (Derivative)
  Date: 2026-08-27 | Code: D | Expires: 2034-08-20 | Exercise: 2025-05-29 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1
• Sold 31,000 shares of Stock Option (right to buy) at $7.54 per share (Derivative)
  Date: 2026-08-27 | Code: D | Expires: 2035-03-20 | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F1, F1
• Sold 18,353 shares of Restricted Stock Units (Derivative)
  Date: 2026-08-27 | Code: D | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F3, F4, F4, F4

Footnotes:

• F1: Pursuant to the Agreement and Plan of Merger, dated July 26, 2026 (the "Merger Agreement"), by and among Forte Biosciences, Inc. ("Company"), argenx BV ("Parent"), and Avena Merger Sub Inc., a wholly owned subsidiary of Parent ("Purchaser"), each unexercised and outstanding option to purchase shares of Common Stock (a "Company Option"), whether or not vested, and which had a per share exercise price that was less than $77.00 per share ("Merger Consideration"), was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the excess (if any) of (a) the Merger Consideration over (b) the per share exercise price subject to such Company Option, multiplied by (y) the total number of shares subject to such Company Option immediately prior to Purchaser merging with and into Company (the "Merger"), with Company surviving the Merger as a wholly owned subsidiary of Parent.
• F2: At the effective time of the Merger, each Company Option that is then outstanding and unexercised, whether or not vested and which has a per share exercise price that is equal to or greater than the Merger Consideration, shall be cancelled with no consideration payable therefor.
• F3: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
• F4: Pursuant to the Merger Agreement, each outstanding restricted stock unit (a "Company RSU"), whether or not vested, was canceled and converted into the right of the holder to receive (i) (subject to any applicable withholding taxes) a lump-sum cash payment equal to (x) the Merger Consideration, multiplied by (y) the total number of shares subject to such Company RSU immediately prior to the effective time of the Merger.